Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olinvacimab - PharmAbcine

Drug Profile

Olinvacimab - PharmAbcine

Alternative Names: Anti-KDR mAb - PharmAbcine; Anti-VEGFR-2-mAb-PharmAbcine; SSS-23; Tanibirumab - PharmAbcine; TTAC-0001

Latest Information Update: 09 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PharmAbcine
  • Developer 3SBio; PharmAbcine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Breast cancer
  • No development reported Cancer; Choroidal neovascularisation; Solid tumours

Most Recent Events

  • 30 Sep 2019 Phase-II clinical trials in Glioblastoma (Recurrent, Second-line therapy or greater) in USA (IV)
  • 17 Sep 2019 PharmAbcine plans a phase II trial for Glioblastoma (Recurrent, Second-line therapy or greater) in USA and Australia (IV) in 2020 (NCT03856099)
  • 17 Sep 2019 PharmAbcine plans a phase II trial for Breast cancer (Metastatic disease) (IV) in 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top